The FDA last week approved a new...

...indication for AstraZeneca's Farxiga. The drug can now be used in type 2 diabetes patients with moderate kidney impairment. Farxiga is found on the preferred tier for 34% of covered lives, and is not covered for 14%. The expanded labeling also applies to AstraZeneca's Xigduo XR. 

SOURCE: MMIT Analytics, as of 3/1/19